Management tracks: BerGenBio, Alzamend

BerGenBio ASA (OSE:BGBIO) said Clinical Development Officer Murray Yule will step down on Nov. 30. The cancer company hired former Amgen Inc. (NASDAQ:AMGN) and AstraZeneca plc (LSE:AZN; NYSE:AZN) leader Alan Barge as interim CMO. Barge left AstraZeneca in 2010 as VP and head of oncology and infection after 12 years with the pharma and was European and global medical director at Amgen from 1990-98. He is SVP of oncology of Aslan Pharmaceuticals Ltd. (TPEx:6497; NASDAQ:ASLN) and CMO of Carrick Therapeutics Ltd. (Dublin, Ireland).

Also on Wednesday, BerGenBio promoted Anthony Brown to CSO from director of research. He succeeds co-founder James Lorens, who will become a senior scientific advisor to the company...